Shield HealthCare has sold a majority interest to Henry Schein
Shield Healthcare has sold a majority ownership position to Henry Schein, Inc. (NASDAQ: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners.
Founded in 1957 and headquartered in Valencia, California, Shield is one of the largest independent value-added distributors of essential medical supplies for patients and caregivers managing care in the home. The company’s diversified product catalog includes durable and consumable medical products for a wide range of patient diagnoses, including incontinence, enteral nutrition, ostomy, urology and advanced wound care. Shield operates across a nationwide footprint to provide superior solutions centered around improving patient outcomes and providing exceptional customer service and patient satisfaction.
Henry Schein is a solutions company for healthcare professionals powered by a network of people and technology. With approximately 24,000 members worldwide, the company’s network of trusted advisors provides over one million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Its business, clinical, technology and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics as well as other alternate care sites.
Oaklins Intrepid in Los Angeles acted as the exclusive sell-side advisor in this transaction.
Talk to the deal team
Adam Abramowitz
Oaklins Intrepid
Kyle Berkman
Oaklins Intrepid
Related deals
Bayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn moreVivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn more